Kyung NAM Pharm경남제약
053950 · KOSDAQ · ₩053950 · 경남제약
₩1,710▼ ₩64 (3.61%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 27.9% | 27.1% | 28.4% | 32.1% | 30.9% | 32.2% |
| Operating margin | −1.3% | −3.1% | 0.0% | −2.2% | −3.9% | −11.2% |
| Net margin | −24.5% | −16.1% | 10.6% | −31.2% | −11.1% | −4.9% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +12.2% | −7.9% | +2.8% | +0.7% | −9.8% | — |
| Operating income growth | +51.9% | −10,383.2% | +101.3% | +44.0% | +68.1% | — |
| Net income growth | −70.6% | −239.9% | +134.9% | −182.9% | −103.8% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −14.4% | −8.1% | 6.5% | −20.1% | −7.5% | −4.4% |
| Return on assets | −10.0% | −5.6% | 4.2% | −12.9% | −4.8% | −2.6% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 21.9% | 43.7% | 44.6% | 68.5% | 44.3% | 71.7% |
| Net debt to equity | −11.3% | −6.6% | −11.6% | 29.7% | −9.1% | 22.5% |
| Current ratio | 276.5% | 171.8% | 168.1% | 100.8% | 171.0% | 216.8% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Kyung NAM Pharm / 경남제약 / 053950 / KRX:053950
Source: KRX statistical information